Non Invasive Biomarkers for Diagnosing Clinically Significant Prostate Cancer

标题 非侵入性生物标志物在前列腺癌诊断中的应用 项目摘要/摘要 尽管许多新诊断的前列腺癌(PC)有懒惰的自然病史， 大多数男性仍在接受与副作用和费用相关的初级治疗， 即过度治疗。显然有必要制定和实施 本地化PC的新管理战略，如果建立在此基础上将得到增强 准确评估疾病状态以及惰性与攻击性的可能性 行为。这项提议将检验这样一种假设，即指示不良PC的生物标志物 特征(例如，高格里森模式)可以在尿液中重复检测到 有个人电脑的人。我们进一步假设，一组非侵入性尿液的初始样本 生物标记物和随着时间的推移对这些标记物的重复评估将与 在前列腺癌中存在显著和不显著的癌症，因此可以 用于为监视或进行最终处理的决定提供信息。该- SE假说将通过设计用于开发不同前列腺的特定目标进行测试 使用定量尿液分析和多机构纵向分析的癌症相关RNA 由主动监测和随之而来的生物检疫、病理- 合乎逻辑的临床数据。 这些目标的成功实现将为早期的 和前列腺癌的纵向评估，以便为准确的治疗提供信息 针对局部疾病的决定。

Title Non-Invasive Biomarkers for Diagnosing Clinically Significant Prostate Cancer Project Summary/Abstract Despite the indolent natural history of many newly diagnosed prostate cancers (PC), most men still undergo primary curative therapy with associated side effects and costs, i.e. overtreatment. There is an clear need for the development and implementation of new management strategies for localized PC which would be enhanced if founded upon accurate assessments of disease status and the potential for indolent versus aggressive behavior. This proposal will test the hypothesis that biomarkers indicative of adverse PC characteristics (e.g. high Gleason pattern) can be reproducibly detected in the urine of men with PC. We further hypothesize that initial sampling of a panel of noninvasive urine biomarkers and the repeated evaluation of these markers over time will associate with the presence of significant versus insignificant cancer in the prostate, and thus can be used in informing decisions for surveillance or proceeding with definitive treatment. The- se hypotheses will be tested through specific aims designed to exploit distinct prostate cancer-associated RNAs using quantitative urine assays and a multi-institutional longitu- dinal cohort of men managed by active surveillance with attendant biospecimens, patho- logical, and clinical data. The successful completion of these aims will provide non-invasive tools for the initial and longitudinal assessment of prostate cancers in order to inform accurate treatment decisions for localized disease.